About 20% of the global population and one in five U.S. adults have elevated levels of lipoprotein(a), a complex form of LDL that strongly predicts risk for coronary disease and aortic valve stenosis. Evidence for a causal association between Lp(a) concentration, which is primarily genetically determined, and CV outcomes across ethnicities continues to build.
FCS is a rare and debilitating genetic disease often leading to significant risk of acute, potentially fatal pancreatitis If approved, olezarsen would be the first approved treatment for FCS in the U.S. CARLSBAD, Calif. , Jan. 31, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc.
Grants & Sponsorships Click on the tabs below to learn more about each of the different grant programs with IONIS, qualifications and requirements for each, and deadlines for submissions.
Ionis Pharmaceuticals, the California company that turned RNA-targeting medicines from an unproven idea into blockbuster drugs, is now expanding into a new class of therapeutics that treat disease by editing DNA.
Ionis Pharmaceuticals has formed an alliance with gene editing startup Metagenomi in a bid to branch out beyond the RNA-based drugs it’s known for.